We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

36 hedge funds and large institutions have $35.1M invested in Regulus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $34.2M → $35.1M (+$861K)

0.11% less ownership

Funds ownership: 0.41% → 0.3% (-0.11%)

22% less funds holding

Funds holding: 46 → 36 (-10)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14

Holders
36
Holders Change
-10
Holders Change %
-21.74%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
11
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$131K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$80.4K
3
WS
Wedbush Securities
California
+$20.2K
4
PAM
Panagora Asset Management
Massachusetts
+$11.7K
5
TSS
Two Sigma Securities
New York
+$4.81K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.21M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$486K
3
SDIC
South Dakota Investment Council
South Dakota
-$361K
4
CS
Candriam SCA
Luxembourg
-$330K
5
DS
DRW Securities
Illinois
-$89K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$3K +$297 +9 +7%
TSS
27
Two Sigma Securities
New York
$3K +$4.81K +146 New
DY
28
Dowling & Yahnke
California
$2K – – –
Barclays
29
Barclays
United Kingdom
$2K +$2.17K +66 +6,600%
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Quebec, Canada
$396 – – –
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$1 – – –
Point72 Asset Management
32
Point72 Asset Management
Connecticut
– -$486K -6,150 Closed
CS
33
Candriam SCA
Luxembourg
– -$330K -4,167 Closed
DS
34
DRW Securities
Illinois
– -$89K -1,125 Closed
ARTA
35
A.R.T. Advisors
New York
– -$24K -304 Closed
Millennium Management
36
Millennium Management
New York
– -$16K -202 Closed
HighTower Advisors
37
HighTower Advisors
Illinois
– -$14K -187 Closed
Macquarie Group
38
Macquarie Group
Australia
– -$13K -167 Closed
TRCT
39
Tower Research Capital (TRC)
New York
– -$13K -162 Closed
Goldman Sachs
40
Goldman Sachs
New York
– -$11K -139 Closed
IA
41
IFP Advisors
Florida
– -$10K -125 Closed
BCM
42
Bourgeon Capital Management
Connecticut
– -$9K -111 Closed
BCM
43
Brookstone Capital Management
Illinois
– -$9K -110 Closed
MAM
44
Meeder Asset Management
Ohio
– -$4.9K -62 Closed
LTFS
45
Ladenburg Thalmann Financial Services
Florida
– -$1.88K -57 -77%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$4K -50 Closed
NFG
47
Next Financial Group
Texas
– +$165 +5 New
1
2

RGLS Hedge Fund Activity: Q3 2018 in Review

36 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2018, worth a combined $35.1M — up 2.5% from $34.2M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of RGLS and 4 opened new positions — a net loss of 10 holders — while 11 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $131K. The largest seller was Fidelity Investments, cutting an estimated $3.21M.

  • 36 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2018, down from 46 in Q2 2018.
  • Funds reported $35.1M of Regulus Therapeutics stock for Q3 2018, up 2.5% quarter-over-quarter.
  • 4 funds opened new Regulus Therapeutics positions in Q3 2018 and 14 closed out, a net change of -10 holders.
  • The largest Regulus Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $131K added.
  • The largest Regulus Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $3.21M sold.

Based on aggregated 13F filings for Q3 2018.